Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Amphetamines”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 271 records · Page 15Linked to original sources

Effects of reserpine on extracellular caudate dopamine and hippocampus norepinephrine responses to amphetamine and cocaine: mechanistic and behavioral considerations.

Following reserpine pretreatment to disrupt vesicular stores of dopamine and norepinephrine, in vivo microdialysis was used in behaving rats to evaluate the role of vesicles in the neurochemical and behavioral responses to amphetamine and cocaine. Reserpine (2.5 mg/kg, 24 hr) completely prevented the hippocampus norepinephrine responses to 20 mg/kg of cocaine and to 0.5, 1.25 and 5.0 mg/kg of amphetamine. Likewise, reserpine almost completely abolished the caudate putamen dopamine response to cocaine. In contrast, the effect of reserpine on the amphetamine-induced dopamine response varied as a function of amphetamine dose. Although the dopamine response to 1.25 mg/kg of amphetamine was unchanged by reserpine pretreatment, the dopamine responses to both the lowest (0.5 mg/kg) and highest (5.0 mg/kg) doses of amphetamine were significantly attenuated by about 65% and 50%, respectively. These results indicate that the norepinephrine response to amphetamine is dependent on vesicular stores of transmitter at all doses of the drug. However, although amphetamine can release dopamine from a reserpine-resistant (non-vesicular) pool, it also appears that this response partially depends on vesicular stores, especially at low and high doses of drug. Concomitant behavioral assessments revealed that the behavioral responses to cocaine and the lowest dose of amphetamine, like the dopamine responses, were significantly suppressed by reserpine pretreatment. In contrast, at the intermediate dose of amphetamine, stereotypies were significantly enhanced. These altered behavioral profiles are discussed in terms of a balance between increases in both dopamine and norepinephrine produced by amphetamine.

Amphetamine↗

d-Amphetamine-induced increase in catecholamine synthesis in the corpus striatum of the rat: persistence of the effect after tolerance.

The effect of d-amphetamine on in vivo catecholamine synthesis in four regions of rat brain was determined by measuring the accumulation of dopa after inhibiton of dopa decarboxylase. In doses up to 2.5 mg/kg, d-amphetamine caused dose-dependent increases in striatal dopa accumulation to a maximum of 280% of control; further increases in dose resulted in smaller effects until 10 mg/kg d-amphetamine was not significantly different from control. d-Amphetamine did not alter dopa accumulation in telencephalon, in diencephalon-mesencephalon, or in pons-medulla oblongata. d-Amphetamine did not affect either dopamine levels in striatum or NE levels in pons-medulla oblongata; at high doses, d-amphetamine did reduce norepinephrine levels in telencephalon and in diencephalon-mesencephalon. Daily administration of pre-session but not of post-session d-amphetamine produced tolerance to the effects of d-amphetamine on milk consumption in rats. The ability of d-amphetamine to increase striatal catecholamine synthesis was not altered by the development of tolerance to d-amphetamine. These results suggest that tolerance to d-amphetamine is not related to its effect on catecholamine synthesis but instead occurs via changes in aspects of catecholamine metabolism other than synthesis via change in catecholamine release, reuptake, or receptor sensitivity, or via changes in non-catecholaminergic mechanisms.

Animals↗

Modification of d-amphetamine-induced responses by baclofen in rats.

RATIONALE: d-Amphetamine is known to have effects on heart rate, body temperature and locomotor activity. However, it is not known if GABAB receptor stimulation modifies these actions of d-amphetamine. OBJECTIVES: Using telemetry recordings, this study examined the interactions between the GABAB receptor agonist baclofen and d-amphetamine, on heart rate responses, body temperature and locomotor activity, and whether these effects could be blocked by the GABAB receptor antagonist SCH 50911. METHODS: Rats were prepared with telemetry implants, which allowed continuous monitoring of heart rate, core temperature and spontaneous locomotor activity. Drugs were subsequently administered subcutaneously to the animals for simultaneous recording over a period of 180 min. RESULTS: d-Amphetamine alone (0.3, 1.0 and 3.0 mg/kg) produced a dose-related increase in heart rate, but was without any effect on body temperature, whilst at 1.0 mg/kg, it significantly increased locomotor activity. Baclofen increased heart rate without affecting locomotor activity, and, at the highest dose of 10.0 mg/kg, it induced a significant reduction in body temperature. Graded doses of baclofen (3.0-10.0 mg/kg), when co-administered with d-amphetamine (1.0 mg/kg), did not modify the d-amphetamine-induced increase in heart rate, but the combination produced significant reductions of body temperature. The latter was only partially reversed by the GABAB receptor antagonist SCH 50911 (10.0 mg/kg). By contrast, the increase in locomotor activity by d-amphetamine was markedly blocked by baclofen in a dose-related manner, and this effect was abolished by SCH 50911 (10.0 mg/kg). SCH 50911 alone at doses of 3.0, 6.0 and 10.0 mg/kg had no effect on temperature or locomotor activity. Heart rate was increased significantly, but the magnitude of change was small. CONCLUSIONS: The results of the present study suggest that stimulation of GABAB receptors by baclofen completely blocks the locomotor stimulatory effects of d-amphetamine. Baclofen did not significantly modify the increase in heart rate produced by d-amphetamine and decreased body temperature, both alone and in combination with d-amphetamine. GABAB receptor ligands may well have potential as pharmacotherapies in the treatment of amphetamine abuse and dependence.

Animals↗

Long-term decreases in striatal dopamine, 3,4-dihydroxyphenylacetic acid, and homovanillic acid after a single injection of amphetamine in iprindole-treated rats: time course and time-dependent interactions with amfonelic acid.

The administration of a single dose of (+)-amphetamine sulfate (9.2 mg/kg) to rats treated with iprindole hydrochloride (10 mg/kg) produced marked decreases in the striatal concentrations of dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC), and homovanillic acid (HVA) one week after drug administration. Significant changes were not observed in striatal 5-hydroxyindoleacetic acid (5-HIAA) nor in norepinephrine, DA, DOPAC, HVA, and 5-HIAA concentrations in frontal cortex and a limbic forebrain sample containing primarily nucleus accumbens and olfactory tubercles. In time-course experiments, decreases in striatal DA were apparent by 12 h after amphetamine plus iprindole administration and persisted for at least 4 weeks. Decreases in striatal DOPAC and HVA followed a similar time course, except decreases in these parameters were observed at 6 h as well. The administration of amfonelic acid, a potent DA uptake inhibitor, up to 8 h but not at 12 h after amphetamine administration prevented the decreases in striatal DA, DOPAC and HVA at on week after the administration of the drug to iprindole-treated rats. These data indicate that the actions of amphetamine which are necessary and sufficient for the production of long-term decreases in striatal DA, DOPAC and HVA are dependent upon the integrity of the neuronal uptake mechanism for DA and occur within 12 h after the administration of amphetamine to iprindole-treated rats. Although amfonelic acid prevented the long-term effects of amphetamine on striatal DA neurons, it did not alter the decrease in DOPAC produced by amphetamine at 6 h after the administration of amphetamine plus iprindole. This finding suggests that the ability of amfonelic acid to prevent the long-term effects of amphetamine on striatal DA neurons in iprindole-treated rats is not due to a blockade of the entry of amphetamine into the neuron and, thus, suggests that the access of amphetamine to the inside of the neuron is not sufficient for the production of its long-term, possibly neurotoxic, effects n striatal DA neurons.

3,4-Dihydroxyphenylacetic Acid↗

Effect of D-amphetamine on the extracellular concentrations of glutamate and dopamine in iprindole-treated rats.

A single administration of D-amphetamine and iprindole has been reported to produce selective, long-lasting decreases in brain dopamine (DA) content because of axon terminal degeneration. It has been found that the noncompetitive glutamate (GLU) antagonist, MK 801, blocks D-amphetamine-induced DA depletion in iprindole-treated rats. In the present study, the effect of D-amphetamine (9.2 mg/kg) and iprindole (10 mg/kg) on the extracellular concentrations of DA and GLU was determined in the striatum of awake, freely moving rats by the use of in vivo microdialysis. D-Amphetamine significantly increased DA and GLU efflux in the striatum of iprindole-treated rats as compared to the vehicle-treated group. The increase in the extracellular concentration of GLU occurred 4-6 hr following drug administration. The concentration of DA was decreased significantly in the striatum of D-amphetamine and iprindole-treated rats 7 days following administration as compared to the vehicle-treated group. Inhibition of tyrosine hydroxylase after alpha-methylparatyrosine (150 mg/kg) administration attenuated D-amphetamine-induced DA and GLU release. The DA antagonist, haloperidol (1 mg/kg), blocked D-amphetamine-induced GLU release without affecting the increase in the extracellular concentration of DA produced by the combination of D-amphetamine and iprindole. Both alpha-methylparatyrosine and haloperidol blocked the depletion of DA in the striatum 7 days after D-amphetamine and iprindole as compared to the vehicle group. In addition, administration of MK-801 (2 mg/kg) 2 hr after D-amphetamine significantly attenuated the long-term (7 day) decrease in striatal DA content produced by the combination of D-amphetamine and iprindole.2+

Animals↗

Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of D-amphetamine.

The inhibitory effects of a variety of established and putative antipsychotic compounds on the hypermotility induced by D-amphetamine at two dose levels (0.5 and 2.0 mg/kg) have been studied. Classical antipsychotics (haloperidol, fluphenazine and cis(Z)-flupentixol) and the selective dopamine D2 receptor antagonist remoxipride inhibit hypermotility in the two conditions with similar potencies, whereas sertindole, clozapine, risperidone, ziprasidone and olanzapine preferentially inhibit the effect of the low dose of D-amphetamine (selectivity ratios between 6.5 and 18). Seroquel, amperozide and the selective 5-HT2A receptor antagonist MDL 100.151 ((+/-)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenylethyl)]-4-p iperidine - methanol) have no effect on D-amphetamine 2.0 mg/kg, but inhibit the response to D-amphetamine 0.5 mg/kg. The alpha 1-adrenoceptor antagonist prazosin inhibits the motility response to D-amphetamine 0.5 mg/kg with slightly higher potency than that to D-amphetamine 2.0 mg/kg, whereas the 5-HT2A/2C receptor antagonist ritanserin selectively inhibits the effect of D-amphetamine 0.5 mg/kg. The histamine H1 receptor antagonist mepyramine is ineffective in both models. All compounds, except remoxipride, MDL 100.151 and ritanserin (which are ineffective) inhibit spontaneous locomotor activity at dose levels close to those inhibiting the response to D-amphetamine 2.0 mg/kg. Prazosin has partial inhibitory effect. In conclusion, dopamine antagonism has similar inhibitory effect on hyperactivity induced by low and high D-amphetamine dosages, alpha 1-adrenoceptor antagonism also contributes to both effects, whereas 5-HT2 receptor antagonism selectively interacts with the low D-amphetamine dose. This indicates that the responses to D-amphetamine 0.5 and 2.0 mg/kg are differently modulated by these neurotransmitters.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗

A behavioral analysis of the effects of amphetamine on play and locomotor activity in the post-weaning rat.

Amphetamine has been shown to canalize or direct the activity of a young rat towards ethologically relevant stimuli. In the five-day-old, amphetamine increases the speed of approach to the nipple of an anesthetized dam; in the 15-day-old, amphetamine increases motor activity and directs it toward an anesthetized adult, however, in the juvenile rat amphetamine reportedly disrupts species-specific behaviors such as huddling and play. The present experiments further assessed the effects of amphetamine in the post-weaning rat by measuring drug-induced behaviors in the presence of an alert and anesthetized companion. In Experiment 1, subjects were videotaped in the presence of an alert non-treated, same-age rat and components of play, a predominant behavior of the post-weaning rat, were recorded. Results confirmed previous reports that low doses of amphetamine (0.5 mg/kg) disrupt play behavior, however, in the present experiment higher doses of amphetamine (1.0 mg/kg) did not disrupt the percentage of time spent in play. Further analysis of drug-induced behavior revealed that the 1.0 mg/kg amphetamine-injected rat engaged in play with the companion, although the drug-treated animal did exhibit marked alterations in the flexibility of its motor patterns. The second experiment confirmed that amphetamine did not disrupt the amount of time a juvenile rat spent with an anesthetized age-mate. In fact, amphetamine-induced activity was directed towards the anesthesized same-age rat. Following amphetamine treatment, all subjects were active nearly 100% of the observation period whether they were tested alone or in the presence of an anesthetized same-age rat.(ABSTRACT TRUNCATED AT 250 WORDS)

Anesthesia↗

d-Amphetamine interaction with glutathione in freshly isolated rat hepatocytes.

Hepatocellular damage has been reported as a consequence of amphetamine intake for which little is known about the respective biological mechanisms involved. To give a better insight of cellular d-amphetamine effects, the present study was performed to evaluate d-amphetamine effects on glutathione homeostasis, in vitro, using freshly isolated rat hepatocytes. Cell viability and lipid peroxidation were also evaluated. Incubation of freshly isolated rat hepatocytes with d-amphetamine (0.08, 0.20, 0.40, and 2.00 mM) induced a concentration dependent glutathione depletion which was observed at all times (1, 2, and 3 h of incubation). After 3 h of incubation, cellular GSH decreased to 85%, 78%, 71% and 47% of control levels for the referred concentrations, respectively. At the third hour of incubation, GSSG levels were only slightly increased for the three higher concentrations of d-amphetamine. The mass spectral study of the methanolic supernatants obtained from hepatocytes incubated with all d-amphetamine concentrations revealed the presence of the p-hydroxyamphetamine glutathione adduct (glutathion-S-yl)-p-hydroxyamphetamine. Pretreatment of hepatocytes with the P450 inhibitors metyrapone (1 mM) and iprindole (10 microM) significantly prevented the glutathione depletion induced by d-amphetamine. This inhibition was more effective for iprindole than for metyrapone. Incubation of isolated hepatocytes with p-hydroxyamphetamine (0.10 mM) for 3 h did not result in any modification of cell viability or GSH or GSSG levels. Also, in the mass spectrum study performed on these samples, the characteristic adduct obtained for d-amphetamine incubations was not detected. The above data suggest that the observed glutathione depletion induced by d-amphetamine is at least in part due to the conversion of d-amphetamine into (glutathion-S-yl)-p-hydroxyamphetamine and that P450 2D seems to have an important role in this metabolism. In spite of the results obtained, showing glutathione homeostasis alterations, incubation of freshly isolated rat hepatocytes with d-amphetamine did not result in any modification of cell viability or lipid redox status.

Animals↗

D-Amphetamine reinstates behavior previously maintained by food: importance of context.

The drug self-administration reinstatement procedure provides an important animal model of relapse. While the procedure is widely used, there has been little investigation of the basic processes involved. This experiment determined the specificity of reinstatement by examining reinstatement of food seeking by D-amphetamine. During training, 24 rats pressed levers for food. Eight rats received 3.0 mg/kg D-amphetamine before and saline after sessions. Eight rats received saline before and after sessions. The final eight rats received saline before and 3.0 mg/kg D-amphetamine after sessions. All rats then experienced saline injections and extinction. During a reinstatement test, all rats received 3.0 mg/kg D-amphetamine. D-Amphetamine significantly increased lever pressing for rats with prior exposure to amphetamine as a predictive cue for food (pre-session) and for rats with no prior exposure to amphetamine. The effect was larger for rats with pre-session exposure to amphetamine than for rats with no previous exposure. Rats with exposure to amphetamine but not as a predictive cue for food (after sessions) did not show significant reinstatement of lever pressing. Therefore, the reinstating effects of amphetamine are not restricted to behavior previously maintained by amphetamine self-administration. In animal models of relapse, reinstatement of drug seeking could be due, in part, to discriminative and direct effects of self-administered drug.

Animals↗

Agonist and antagonist activity of low efficacy D2 dopamine receptor agonists in rats discriminating d-amphetamine from saline.

The ability of the low efficacy D2 agonists preclamol and SDZ 208-911 to both antagonise, and substitute for, the d-amphetamine discriminative cue was investigated in rats trained to discriminate d-amphetamine (0.5mg/kg) from saline. All doses of preclamol (2.0-16.0mg/kg) and SDZ 208-911 (0.125-1.0mg/kg) only partially antagonised d-amphetamine discrimination. In contrast, the lower efficacy D2 agonist SDZ 208-912 completely blocked the cueing properties of d-amphetamine. Preclamol (4.0 and 16.0mg/kg) and SDZ 208-911 (1.0mg/kg) also partially substituted for d-amphetamine. In an additional study, the former drug enhanced the discriminative effects of a low dose of d-amphetamine (0.125mg/kg), whilst antagonising the effects of the training dose. Preclamol also partially antagonised the ability of the selective D2 agonist quinpirole (0.125mg/kg) to substitute for d-amphetamine. In contrast to the drug discrimination findings, preclamol completely antagonised the locomotor hyperactivity induced by acute d-amphetamine, in animals which had received the same long-term d-amphetamine treatment as the drug discrimination rats. The present findings reveal that preclamol and SDZ 208-911 can exert both agonist and antagonist activity in animals trained to discriminate d-amphetamine from saline. This partial agonist profile is probably due to the low efficacy D2 agonists interacting with a postsynaptic D2 receptor population possessing a higher response capability than those D2 receptors mediating d-amphetamine-induced locomotor hyperactivity.

Journal Article↗

The existence of tolerance to and cross-tolerance between d-amphetamine and methylphenidate for their effects on milk consumption and on differential-reinforcement-of-low-rate performance in the rat.

Administration of d-amphetamine (2.5 mg/kg) or methylphenidate (20 mg/kg) decreased milk consumption in rats. When these drugs were administered daily, tolerance developed to this effect over the course of 20 days. Cross-tolerance to the effects on milk consumption occurred between d-amphetamine and methylphenidate over a 4-fold range of dose of both drugs. Administration of d-amphetamine (1.5 mg/kg) or methylphenidate (10 mg/kg) disrupted responding under differential-reinforcement-or-low-rate (DRL) contingencies. Both drugs increased response rate, decreased frequency of reinforcement and shifted the mode of the inter-response time distribution to the left. When the drugs were administered daily, tolerance developed to all these effects over the course of 20 days. Cross-tolerance to the effects on DRL behavior occurred between d-amphetamine and methylphenidate over a 4-fold range of dose of both drugs. Daily administration of d-amphetamine (2.5 mg/kg) but not of methylphenidate (20 mg/kg) resulted in decreased norepinephrine (NE) levels in brain; the decreased norepinephrine levels, which occur with repeated d-amphetamine administration, are believed to result from the storage in noradrenergic neurons of p-hydroxynorephedrine, a metabolite of d-amphetamine. Radioactivity was not detectable in brain 24 hours after the last of 15 daily doses of radiolabeled methylphenidate. These results suggest that d-amphetamine, but not methylphenidate, is metabolized to a compound which is stored in noradrenergic neurons. The existence of behavioral cross-tolerance between d-amphetamine and methylphenidate is therefore inconsistent with the hypothesis that tolerance to the behavioral effects of d-amphetamine is due to the metabolism of d-amphetamine to p-hydroxynorephedrine, a false transmitter in noradrenergic neurons.

Animals↗

Adderall produces increased striatal dopamine release and a prolonged time course compared to amphetamine isomers.

RATIONALE: Adderall is currently used for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) and is composed of a novel mixture of approximately 24% L-amphetamine and 76% D-amphetamine salts. There are, however, no investigations of the pharmacological effects of this combination in vivo. OBJECTIVES: The technique of high-speed chronoamperometry using Nafion-coated single carbon-fiber microelectrodes was used to study amphetamine-evoked dopamine (DA) release produced by Adderall, D-amphetamine, or D,L-amphetamine in the striatum of anesthetized male Fischer 344 (F344) rats. The amphetamine solutions were locally applied from micropipettes by pressure ejection. RESULTS: Local applications of Adderall resulted in significantly greater DA release signal amplitudes with prolonged time course of dopamine release and re-uptake as compared to D-amphetamine and D,L-amphetamine. CONCLUSIONS: These data support the hypothesis that the combination of amphetamine enantiomers and salts in Adderall has effects on DA release, which result in increased and prolonged DA release, compared to D- and D,L-amphetamine.

Amphetamine↗

Effects of repeated withdrawal from continuous amphetamine administration on brain reward function in rats.

RATIONALE: The study of the effects of repeated amphetamine administration and withdrawal on brain reward function has relevance to both amphetamine dependence and non-drug-induced depressions. OBJECTIVES: The purpose of this study was to investigate the effects of continuous amphetamine administration and withdrawal on brain stimulation reward thresholds, and the changes that occur with repeated amphetamine exposures. METHODS: Rats were prepared with bipolar electrodes in the lateral hypothalamus and trained in a discrete-trial reward threshold procedure. Then, rats underwent two separate periods of amphetamine administration via subcutaneous osmotic mini-pumps. RESULTS: Continuous amphetamine administration was associated with lowering in brain reward thresholds and decreases in response latencies, while withdrawal was associated with threshold elevations. These effects changed with subsequent amphetamine administration and withdrawal. CONCLUSIONS: The results of this study indicated that with the amphetamine administration regime used here, rats developed increased sensitivity to the effects of acute amphetamine administration and tolerance to the effects of amphetamine withdrawal.

Amphetamine↗

Effects of environmental enrichment on extinction and reinstatement of amphetamine self-administration and sucrose-maintained responding.

The current experiments aimed to determine whether differential rearing alters extinction and/or reinstatement of amphetamine self-administration or sucrose-maintained responding. Male Sprague-Dawley rats were raised in either an enriched condition or an isolated condition. Rats were then trained to lever press on a continuous reinforcement schedule across either 15 daily amphetamine self-administration sessions or 15 sucrose-reinforced sessions, followed by 10 sessions of extinction. After the extinction sessions, priming doses of amphetamine (0, 0.25 or 1.0 mg/kg) were administered 15 min before the session, or sucrose (one or 10 pellets) was delivered non-contingently at the beginning of the session. Enriched condition rats showed greater extinction for amphetamine and sucrose-maintained responding than isolated condition rats. When primed with amphetamine, isolated condition rats reinstated responding following 0.25 mg/kg of amphetamine, whereas enriched condition rats only reinstated responding after 1.0 mg/kg of amphetamine. Isolated condition rats failed to reinstate responding following sucrose delivery, while enriched condition rats reinstated responding following the delivery of 10 sucrose pellets. These results indicate that environmental enrichment enhanced the extinction of both amphetamine and sucrose-maintained responding. Environmental enrichment also raised the reinstatement threshold specific to the amphetamine prime, suggesting a reduction in the incentive motivational effect of amphetamine.

Amphetamine↗

Differential effects of amphetamine transport vs. dopamine reverse transport on particulate PKC activity in striatal synaptoneurosomes.

Amphetamine has been shown to increase striatal particulate protein kinase C (PKC) activity [Giambalvo (1992b) Neuropharmacology 31:1211-1222]. The present study examined possible mechanisms involved. Specifically, the effects of calcium, endogenous DA, and DA receptors on the amphetamine-induced increase in PKC activity in striatal synaptoneurosomes were examined. Naïve rats and rats pretreated with N-ethoxy-carbonyl-2-ethoxy-1,2-dihydroquinolone (EEDQ, i.p.), a nonselective irreversible receptor antagonist, or with alpha-methyl-p-tyrosine (AMPT, i.p.), a DA synthesis inhibitor, were sacrificed and striatal synaptoneurosomes were prepared. The tissue was incubated with amphetamine, with and without calcium, and PKC activity was then determined by the endogenous phosphorylation of endogenous substrate proteins, as described previously [Giambalvo (1988a) Biochem Pharmacol 37:4001-4007]. It was found that calcium enhanced the effect of amphetamine on PKC activity, even in rats pretreated with EEDQ. Intracellular calcium was required since pretreatment with 1,2-bis (2-aminophenoxy) ethane-N, N, N, N-tetracetic acid acetoxymethyl ester (BAPTA-AM) in vitro attenuated the amphetamine-induced increase in PKC activity, resulting in an inhibition of PKC activity instead. Likewise, endogenous DA was essential since pretreatment with AMPT resulted in a similar amphetamine-induced inhibition of PKC activity. Pretreatment with AMPT did not alter the inhibitory effect of the D2 DA agonist, LY 171555, on PKC activity. It did, however, abolish the calcium-dependent stimulatory effect of the D1 agonist SKF 38393 on PKC activity, rendering it inhibitory regardless of calcium. Considering that both BAPTA-AM and AMPT pretreatments, which diminished DA release without affecting uptake via different mechanisms, produced similar inhibitory effects on PKC activity by amphetamine, these results suggest that the inward transport of amphetamine had an inhibitory effect on PKC activity. In contrast, the outward transport of DA seemed to have a stimulatory effect on PKC activity since incubation with low sodium or with ouabain, conditions that promote DA reverse-transport, increased PKC activity. These results showed that PKC activity was altered differently during inward vs. outward transport. The amphetamine-induced increase in PKC activity was attenuated by pretreatment with DA uptake blockers (nomifensine, GBR 12935, and bupropion), even though these drugs by themselves also increased PKC activity. This effect was diminished by calcium and persisted in rats pretreated with EEDQ. Thus, calcium had a differential effect on the PKC activity induced by a transported substrate (amphetamine) vs. nontransported inhibitors (DA uptake blockers).

Amphetamine↗

Amphetamine-induced time-dependent sensitization of dopamine neurotransmission in the dorsal and ventral striatum: a microdialysis study in behaving rats.

The purpose of this study was to compare the effects of amphetamine exposure on subsequent amphetamine-induced changes in behavior and dopamine (DA) release in the dorsal and ventral striatum, as a function of time following the discontinuation of repeated amphetamine treatment. Rats were pretreated with either saline or an escalating-dose amphetamine regimen, and then received a 0.5 mg/kg amphetamine "challenge" after either 3, 7, or 28 days of withdrawal. Animals tested after 28 days of withdrawal were hypersensitive (sensitized) to the locomotor-activating effects of amphetamine, and relative to control animals showed a significant enhancement in amphetamine-stimulated DA release in both the dorsal and ventral striatum, as revealed by in vivo microdialysis. Animals tested after only 3 or 7 days of withdrawal showed neither behavioral sensitization nor enhanced amphetamine-stimulated DA release. These results establish that time-dependent changes in behavioral sensitization to amphetamine are associated with time-dependent changes in amphetamine-stimulated DA release, and support the hypothesis that persistent sensitization-related changes in striatal DA neurotransmission contribute to the expression of behavioral sensitization.

Amphetamine↗

Facilitating effect of amphetamine on the response of rabbit aortic strips to adrenaline, dopamine and serotonin.

Amphetamine increased the response of rabbit aortic strips to adrenaline, dopamine and serotonin at consistently lower doses than those exerting a direct contracting effect. The amphetamine-facilitated contraction had the same shape as that produced by biogenic amines alone, whereas the contraction produced by amphetamine alone was more delayed and flatter. Serotonin and dopamine facilitated each other, but less markedly and with a narrower interval between facilitating and contracting doses than amphetamine. Pargyline exerted no facilitating effect on biogenic amines. Phentolamine and prazosin inhibited the direct response to adrenaline, dopamine and amphetamine, and the amphetamine-facilitated response to adrenaline and dopamine; they were inactive against serotonin alone and combined with a facilitating dose of amphetamine or dopamine. Cyproheptadine inhibited the direct response to serotonin and amphetamine, and the amphetamine-facilitated response to serotonin; it was inactive against dopamine and adrenaline both alone and combined with a facilitating dose of amphetamine or serotonin.

Amphetamine↗

Evidence for dissociable mechanisms of amphetamine- and stress-induced behavioral sensitization: effects of MK-801 and haloperidol pretreatment.

The present study examined the ability of pretreatment with MK-801 or haloperidol to block the induction of behavioral sensitization to amphetamine challenge by repeated immobilization stress in male Sprague-Dawley rats. Fifteen minutes before each of ten 30-min restraint sessions, rats were administered saline, MK-801 (0.01, 0.10 or 0.25 mg/kg i.p.) or haloperidol (0.10 or 0.25 mg/kg i.p.). Control rats received the same injection regimen without restraint. An additional experiment examined the ability of MK-801 to block the induction of sensitization by repeated d-amphetamine. In this experiment, rats were administered saline or MK-801 (0.25 mg/kg i.p.) 15 min before each of ten amphetamine injections (1.0 mg/kg i.p., administered under the same regimen as immobilization stress). Four days after the final immobilization or amphetamine injection, rats were tested for locomotor response to novelty, saline and d-amphetamine (1.5 mg/kg i.p.). Exposure to repeated immobilization stress significantly enhanced the locomotor response to amphetamine challenge but not to saline challenge whether rats were pretreated with saline, MK-801 or haloperidol. Secondary analysis of dose effects in each pretreatment group revealed that at 0.25 mg/kg, repeated MK-801 in itself induced sensitization to the response to amphetamine in control rats and potentiated stress-induced sensitization in restrained rats. In contrast, the sensitization induced by repeated amphetamine was attenuated by MK-801 pretreatment. Neither dose of haloperidol affected the locomotor response to saline or amphetamine in control or stressed rats. These results indicate that the effects of MK-801 on the induction of sensitization are complex and suggest that amphetamine- and stress-induced behavioral sensitization may arise through different mechanisms.

Amphetamine↗